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Cord blood (CB) transplantation in adults is limited by low cell
dose. This leads to delayed engraftment and delayed immune
reconstitution with susceptibility to infections a major cause of
morbidity and mortality. We hypothesize that the infusion of ex
vivo CB T cells expanded using an anti-CD3/anti-CD28 bead may
provide more rapid immune reconstitution, thereby reducing in-
fectious complications. Prior to initiating a clinical trial, conditions
for ex vivo CB T cell expansion need to be optimized. Variables
investigated include addition of N-acetylcysteine (NAC) to culture
(potentially reducing apoptosis), optimizing levels of interleukin 2
(IL-2), and continuous addition of anti-CD3/anti-CD28 beads to
maintain a bead to cell ratio of 3:1. Methods: CB T cells were
isolated from CB sample using anti-CD3/anti-CD28 paramagnetic
beads and co-cultured with beads for a total of 14–28 days. Com-
parisons included: (1) 0 versus 10 mM NAC; (2) maintained 3:1
bead:cell ratio versus dilution with culture; (3) IL-2 concentration
(0, 20, 200, 2000, and 20,000 IU/mL). Phenotypes were investi-
gated using ﬂow cytometry and T cell receptor diversity measured
by spectratyping. Results: Overall, 300–1200-fold increases in T
cell numbers were achieved. (1) While NAC did not signiﬁcantly
impact cell numbers, ﬂow cytometry suggested cell death was
reduced. (2) Maintaining a constant bead to cell ratio throughout
culture did not improve proliferation. (3) Greatest T cell prolifer-
ation was obtained when 2000 and 20,000 IU/mL IL-2 were used.
At the time of maximal expansion, the majority of the CD4 cells
retained a naive phenotype (CD27CD28). A small proportion of
late stage “effector” cells were present (CD27CD28 or
CCR7CD45RA). CD8 T cell differentiation toward a “mem-
ory” phenotype (CD27CD28 or CD27CD28, or
CCR7CD45RA or CCR7CD45RA) was observed. Signiﬁ-
cantly, the expanded CB T cells retained a polyclonal TCR diver-
sity. Conclusions: These preliminary data suggest that the ex vivo
expansion of CB T cells may yield sufﬁcient numbers of T cells to
potentially improve immune reconstitution in CB recipients and
reduce post-transplant mortality. Studies assessing the functional-
ity of the expanded T cells are currently underway.
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Immunoincompetence after allogeneic hematopoietic stem cell
transplantation (HSCT) particularly affects the T cell lineage re-
sulting in signiﬁcant morbidity and mortality from opportunistic
infections. Recent studies have shown that murine T cells and their
precursors can be generated from hematopoietic stem cells (HSC)
in vitro using OP9 bone marrow stromal cells (H2Kk/H2Kb)
expressing the Notch 1 ligand Delta-like 1 and growth factors. In
this study we determined the effects of adoptively transferred in
vitro generated T cell precursors on T cell reconstitution after
allogeneic HSCT. We selected HSC (Lin-Sca-1hi c-kit) from
mouse bone marrow (BM) of various strains and cultured these
cells on a monolayer of OP9-DL1 cells in the presence of growth
factors. T lineage cell development proved to be strain indepen-
dent and is therefore not MHC restricted in this culture system.
C57BL/6 dervied HSC expanded 2000–5000-fold within 3–4
weeks and consisted of 90–95% CD4-CD8-double negative (DN)
T cell precursors after 16–28 days of culture. We infused these
cells (8106) with T cell depleted (TCD) BM (5 106) or puriﬁed
HSC into allogeneic recipients using minor antigen mismatched
and MHC class I/II mismatched transplant models. Progeny of
OP9-DL1 derived T cell precursors were found in the thymus and
the periphery signiﬁcantly improving thymic cellularity, and thy-
mic and splenic donor T cell chimerism. Combination of T cell
precursor administration and pre-conditioning with keratinocyte
growth factor (KGF) further improved thymic engraftment of
OP9-DL1 derived T cell precursors. T cell receptor repertoire and
proliferative response to foreign antigen of OP9-DL1 derived
mature T cells were intact. Moreover, Th1-type cytokine secretion
of OP9-DL1 derived splenic T cells after stimulation with PMA/
ionomycin was better than that of BM or HSC derived donor T
cells. Progeny of OP9-DL1-derived T cell precursors remained
detectable for at least 60 days after transplant with intact cytokine
production. Administration of in vitro generated T cell precursors
did not induce GVHD but mediated signiﬁcant graft-versus-tumor
(GVT) activity (determined by in vivo bioluminescence imaging)
resulting in a subsequent signiﬁcant survival beneﬁt. We conclude
that the adoptive transfer of OP9-DL1 derived T cell precursors
signiﬁcantly enhances donor T cell reconstitution in allogeneic
HSCT recipients and results in GVT activity in the absence of
GVHD.
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Adenovirus is a signiﬁcant cause of morbidity and mortality in
pediatric HSCT patients. Severity of immune suppression appears
to be the most important risk factor for serious Ad disease. With-
out proven antiviral therapy, cellular immunity is the most effective
protection against Ad disease. To better understand Ad immune
recovery post-BMT, we prospectively monitored viral load, Ad
subtype infection rates, and recovery of Ad cellular immunity in 22
pediatric HSCT patients (ages 14 months–20 years) who received
matched-related (MRD n  6), mismatched related (haplo n  6),
or unrelated donor (MUD n  10) grafts. Real-time PCR (Q-
PCR) provided quantitative measure of Ad viral load and detected
Ad in blood samples from 68% (15/22) of patients on at least one
occasion post SCT. 2/6 MRD recipients had Ad detected in their
blood vs 8/10 MUD and 5/6 haplo patients. 13/16 (81%) of
patients who provided stool samples were ve for Ad on at least
one occasion. Ad subgroup C predominated in blood (93%), while
subgroups varied in stool: A(62%), B(12%), C(62%), D(6%),
E(6%), F/G(44%). 8/16 patients were positive for multiple sub-
types in their stool. Mean Ad-speciﬁc spot forming cells (SFC)/1
106 PBMC as measured by IFNg ELISPOT assay was not signif-
icantly different in the MRD and MUD groups at 3, 6, and 12
months post HSCT (P  .1). At 3 months, MUD patients had
mean 29 SFC/106cells (range: 0–190) versus 27 SFC/106 cells
(range: 0–100) in the MRD group. By 12months, MUD patients
had 63 (0–225) versus 78(17–201) SFC/106 cells in MRD group.
However, immune response to adenovirus was signiﬁcantly de-
layed (P  .005) in Haplo patients at 3months (4 SFC/106cells,
range:0–18) and 12months (23 SFC/106cells, range:0–60). Mor-
tality from adenovirus was 4.5% (1/22). Mean ALC in MUD,
MRD, and Haplo recipients at 12 months were:1901/ul (772–
3728), 2153/ul (948–3280), 1713/ul (1128–2406), respectively
(P 	 .1). Mean CD4 and CD8 counts/l in MUD, MRD, and
Haplo recipients at 12months were: 835 (range:37–1656) and 589
(range:18–2404), 1373 (560–2169) and 530 (332–706), and 1055
(451– 1659) and 398 (178–620), respectively (P 	 .1). In conclu-
sion, our data shows recipients of T cell depleted HSCT products
from haploidentical donors have signiﬁcantly delayed Ad-speciﬁc
cellular immune recovery. Further, ALC does not predict speciﬁc
immune recovery to adenovirus. We have initiated a clinical study
of donor-derived adenovirus-speciﬁc CTL infusions for the pro-
phylaxis and treatment of Ad infection post SCT that will target
this patient population.
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